Compare CLBK & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLBK | WGS |
|---|---|---|
| Founded | 1927 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Savings Institutions | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2017 | N/A |
| Metric | CLBK | WGS |
|---|---|---|
| Price | $17.96 | $67.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $17.00 | ★ $120.71 |
| AVG Volume (30 Days) | 179.3K | ★ 628.0K |
| Earning Date | 04-20-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 563.64 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.97 | $29.98 |
| Revenue Next Year | $11.43 | $25.92 |
| P/E Ratio | ★ $36.15 | $1,251.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.56 | $55.17 |
| 52 Week High | $18.87 | $170.87 |
| Indicator | CLBK | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 51.05 | 49.94 |
| Support Level | $17.82 | $68.55 |
| Resistance Level | $18.71 | $95.75 |
| Average True Range (ATR) | 0.32 | 4.26 |
| MACD | 0.03 | 1.54 |
| Stochastic Oscillator | 47.23 | 73.04 |
Columbia Financial Inc is a federally chartered savings bank that serves the financial needs of depositors and the local community as a community-minded, customer service-focused institution. It offers traditional financial services to businesses and consumers. It attracts deposits from the general public and uses those funds to originate a variety of loans, including multifamily and commercial real estate loans, commercial business loans, one-to-four family real estate loans, construction loans, home equity loans and advances, and other consumer loans, and also offers a broad range of insurance products, investment solutions, and wealth management services.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.